Manufacturing Cellares and Papillon partner for PPL-001 manufacturing automation Pharmaceutical Business ReviewPPL-001 is a gene-corrected haematopoietic stem and progenitor cell (HSPC) therapy.Read full story pharminent July 22, 2026 (Last updated: July 27, 2026) Pharmaceutical Business Review PPL-001 is a gene-corrected haematopoietic stem and progenitor cell (HSPC) therapy. Read full story Post navigation Previous: Novo Nordisk Sues Eli Lilly Over ‘Deceptive’ GLP-1 AdvertisingNext: US generic tariff reprieve on the rocks as Trump proposes 100% rate in 2028 Related Stories Manufacturing Sandoz plans ‘vast and vertically integrated’ supply chain to support 100-biosimilar vision pharminent September 9, 2026 Manufacturing US puts $125m into personalised RNA therapy production pharminent September 2, 2026 Manufacturing Multispecifics are transforming the CDMO development architecture pharminent August 28, 2026